Expert Highlights Advances in Treatment Landscape for Advanced Bladder Carcinoma

Neal Shore, MD, discusses the current outlook for the treatment landscape in advanced or metastatic urothelial carcinoma.

Neal Shore, MD, director, Carolina Urologic Research Center, discusses the current outlook for the treatment landscape in advanced or metastatic urothelial carcinoma.

The landscape has evolved dramatically due, in part, to the increased understanding of advanced disease, which led to the approval of 5 encouraging checkpoint inhibitor therapies, and approval of other novel therapies as well. These are truly remarkable improvements, Shore says.

We have also gained improved understanding of the use of immunotherapy in the frontline, as well as in the second-line and maintenance settings for patients with metastatic urothelial carcinoma. Among other advances in the field, Shore highlights the approval of erdafitinib (Balversa) and enfortumab vedotin-ejfv (Padcev), and these therapies all provide expanded treatment options for patients with metastatic disease who either failed or weren’t candidates for radical cystectomy.